A natural carbohydrate-based cryoprotective agent offering proven efficacy with reduced toxicity compared to high concentrations of DMSO, PentaHibe comes in a number of formulations to suit your needs.
PentaHibe Complete is a ready-to-use cGMP compliant formulation that can be used with a range of cell types. With 10% pentaisomaltose and 2% DMSO as cryoprotective agents, PentaHibe Complete significantly reduces DMSO-related toxicity and side effects.
PentaHibe Complete, containing 2% DMSO, shows comparable results to commercially available cryosolutions with higher DMSO concentration and even demonstrates superior migratory potential.
PentaHibe Complete, containing 2% DMSO, minimizes cellular toxicity and DMSO-related side effects, enhancing both safety and effectiveness vs. traditional DMSO-based cryopreservation methods.
PentaHibe Complete, cGMP manufactured, has been tested on T-cells, human mesenchymal stem cells, and CHO cells and comes with comprehensive documentation to support regulatory submissions.
PentaHibe Base (40% pentaisomaltose) is a natural, cGMP compliant, non-toxic cryoprotective agent that can be used as the sole cryoprotective agent or as a base for further formulations. In addition to offering complete flexibility, PentaHibe Base can eliminate the need for DMSO or reduce the need for DMSO to 1-2%, which significantly lowers DMSO-related toxicity and side effects.
DMSO-free PentaHibe Base can be used as sole CPA for cryopreservation of hematopoietic stem cells and ensures the same recovery as with 10% DMSO
10% PentaHibe Base and only 1% DMSO show similar viability and recovery to commercial formulations with 10% DMSO for cryopreservation of T cells
Preclinical and clinical studies confirm pentaisomaltose’s tolerability in both humans and various animal species, supported by comprehensive pharmaco-toxicological and clinical evidence.